** Shares of drug developer Cargo Therapeutics CRGX.O rise 21% to $4.60 premarket
** On Tuesday, co said it is reducing its workforce by about 90%
** CRGX appointed Anup Radhakrishnan as interim CEO to lead the co through a potential merger or acquisition
** As of December 31, 2024, co had about 167 full-time employees - SEC filing
** Co also said it is stopping its experimental cancer therapy, CRG-023, and allogeneic platform
** Earlier this year, co halted a mid-stage trial for cancer treatment
** CRGX has $368.1 million in cash, as of December 31, 2024
** CRGX fell 36.5% last year
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.